VSTM מכפיל P/S עתידי Verastem
Verastem, Inc. (VSTM) currently has no commercial sales, however, the future launch of targeted drugs will enable premium pricing. High pricing power is expected due to avutometinib, which blocks tumor regeneration. The future P/S multiple valuation on GURU.Markets confirms long-term sustainability, where the latest value is recorded as 10.60. Proprietary developments will allow the company to monetize proven oncology therapy courses for years.
Verastem Corp - פילוחים אנליטיים ומדדי מפתח (VSTM)
The forward P/S ratio reflects the market value of a business relative to its projected annual revenue. By analyzing the forward P/S trend, an investor determines the extent of the premium paid for future cash flows. The metric is calculated as the ratio of current market capitalization to expected sales volume. For Verastem, Inc. (VSTM), this indicator is critical, as it assesses the speculative value of the R&D pipeline and the probability of success for avutometinib therapy.
